The Australian medicine subsidy record.
Every published PBAC decision, and what happened after.
Or pose a research brief and let it work the record — every claim quoted from the document it cites.
Also in the file: diseases (NICE appraisals sit on the condition, not as a verdict), insights, the cycle briefing, and how we work.
Recently published summaries
| Drug | Therapy | Indication | Outcome | Decided |
|---|---|---|---|---|
| Adalimumab | Rheumatology | Moderate to severe ulcerative colitis, severe Crohn disease, severe chronic plaque psoriasis, vision threatening non-infectious uveitis, sev | Recommended · restricted | Mar 2026 |
| Adalimumab | Rheumatology | Treatment of multiple autoimmune conditions including severe Crohn disease, moderate to severe ulcerative colitis, severe active rheumatoid | Recommended · restricted | Mar 2026 |
| Adrenaline (Epinephrine) | Immunology | Emergency treatment of acute severe allergic reactions in children or adults at significant risk of anaphylaxis. | Recommended · restricted | Mar 2026 |
| Alectinib | Oncology | Adjuvant therapy for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) after tumour resection in patients with tu | Recommended · restricted | Mar 2026 |
| Amivantamab | Oncology | Treatment of patients with epidermal growth factor receptor gene mutated (EGFRm) locally advanced/metastatic non-small cell lung cancer (NSC | Recommended · restricted | Mar 2026 |
| Respiratory Syncytial Virus Vaccine, Recombinant, Pre-Fusion F Protein 3, Older Adult | Vaccines | Prevention of RSV-confirmed lower respiratory tract disease (LRTD) in adults aged ≥75 years, First Nations adults aged 60-74 years, and adul | Recommended | Mar 2026 |
| Asciminib | Haematology | Addition of nurse practitioners as eligible prescribers for continuing treatment phases of asciminib in patients with Ph+ CML (chronic phase | Recommended · restricted | Mar 2026 |
| Avacincaptad Pegol | Ophthalmology | Treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who have an intact fovea and wh | Recommended · restricted | Mar 2026 |
| Canakinumab | Rare disease | Treatment of paediatric colchicine-resistant or intolerant familial Mediterranean fever (FMF) patients who continue canakinumab treatment in | Recommended · restricted | Mar 2026 |
| Cannabidiol | Neurology | Severe myoclonic epilepsy in infancy (Dravet syndrome) — treatment of generalised tonic-clonic seizures or generalised clonic seizures that | Recommended · restricted | Mar 2026 |
| Ciclosporin | Ophthalmology | Chronic severe dry eye disease with keratitis in adult patients whose condition has not been adequately controlled by monotherapy with an ar | Recommended · restricted | Mar 2026 |
| Dupilumab | Respiratory | Add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation (defined by b | Recommended · restricted | Mar 2026 |
| Durvalumab | Oncology | Perioperative treatment (neoadjuvant and adjuvant) of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma who | Recommended · restricted | Mar 2026 |
| Efgartigimod Alfa | Neurology | Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. | Recommended · restricted | Mar 2026 |
| Enzalutamide | Oncology | Treatment of non-metastatic hormone sensitive prostate cancer (m0HSPC) with high-risk biochemical recurrence (PSA doubling time ≤9 months) i | Recommended · restricted | Mar 2026 |
| Glycomacropeptide Formula With Long Chain Polyunsaturated Fatty Acids And Docosahexaenoic Acid And Low In Phenylalanine | Metabolic | Dietary management of phenylketonuria (PKU) in children from 3 years of age and adults. | Recommended · restricted | Mar 2026 |
| Incobotulinumtoxina | Neurology | Moderate to severe spasticity of the lower limb in adults following stroke, traumatic brain injury, or spinal cord injury. | Recommended · restricted | Mar 2026 |
| Inotuzumab Ozogamicin | Haematology | Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (B-ALL), including Philadelphia chromosome-positive dise | Noted | Mar 2026 |
| Lanreotide | Endocrinology | Treatment of acromegaly, functional carcinoid tumour, and non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET). | Recommended | Mar 2026 |
| Loncastuximab Tesirine | Haematology | Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received two or more prior lines of s | Not recommended | Mar 2026 |
| Mepolizumab | Respiratory | Add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype (blood | Recommended · restricted | Mar 2026 |
| Nemolizumab | Dermatology | Treatment of patients aged 12 years or older with chronic severe atopic dermatitis affecting the whole body, face, and/or hands who are inad | Recommended · restricted | Mar 2026 |
| Nivolumab | Oncology | Treatment of multiple advanced or metastatic cancers including melanoma, NSCLC, RCC, urothelial carcinoma, squamous cell carcinoma of the or | Not recommended | Mar 2026 |
| Obinutuzumab | Rheumatology | Treatment of adult patients with active class III or IV lupus nephritis with or without class V disease who are receiving standard therapy w | Recommended · restricted | Mar 2026 |
| Odevixibat | Hepatology | Treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged six months and older. | Not recommended | Mar 2026 |
| Omalizumab | Respiratory | Treatment of uncontrolled severe asthma (USA), uncontrolled severe allergic asthma (USAA), and severe chronic spontaneous urticaria (CSU) in | Recommended · restricted | Mar 2026 |
| Pegcetacoplan | Rare disease | Treatment of patients aged 12 years and older with complement 3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomeru | Not recommended | Mar 2026 |
| Pegvaliase | Metabolic | Treatment of patients aged 16 years and older with hyperphenylalaninemia due to phenylketonuria (PKU) who have inadequate blood phenylalanin | Deferred | Mar 2026 |
| Retifanlimab | Oncology | Treatment of metastatic or recurrent, locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation. | Recommended · restricted | Mar 2026 |
| Retifanlimab | Oncology | Treatment of inoperable locally recurrent or metastatic squamous cell anal carcinoma (SCAC) not previously treated with systemic chemotherap | Recommended · restricted | Mar 2026 |
| Riluzole | Neurology | Treatment of amyotrophic lateral sclerosis (ALS), specifically in patients who experience dysphagia and/or require percutaneous endoscopic g | Noted | Mar 2026 |
| Risperidone | Mental health | Prevention of relapse of schizophrenia in adults following stabilisation with oral risperidone. | Recommended · restricted | Mar 2026 |
| Romidepsin | Oncology | Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following at least one prior systemic therapy. | Recommended · restricted | Mar 2026 |
| Ruxolitinib | Haematology | Addition of nurse practitioners as prescriber type for existing PBS-listed ruxolitinib for treatment of myelofibrosis, polycythemia vera, ac | Recommended · restricted | Mar 2026 |
| Selpercatinib | Oncology | Advanced or metastatic medullary thyroid cancer (MTC) with RET variants in patients with unresectable disease and documented disease progres | Recommended · restricted | Mar 2026 |
| Mrna-1273 | Vaccines | Prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in adults aged 75 years or more (2 doses per year), adults aged 65-74 | Deferred | Mar 2026 |
| Tafamidis | Cardiovascular | Treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), specifically in patients with NYHA class I-II heart failure. | Not recommended | Mar 2026 |
| Tafasitamab | Haematology | Relapsed or refractory follicular lymphoma in patients who have had at least 1 prior systemic anti-CD20 therapy, treated in combination with | Recommended · restricted | Mar 2026 |
| Tarlatamab | Oncology | Treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemot | Not recommended | Mar 2026 |
| Teclistamab | Oncology | Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 3 prior lines of therapy, includi | Recommended · restricted | Mar 2026 |
| Tildrakizumab | Dermatology | Continuing treatment of adults with severe chronic plaque psoriasis who have achieved at least a PASI75 response with tildrakizumab 100 mg. | Recommended | Mar 2026 |
| Tirzepatide | Endocrinology | Treatment of adults with type 2 diabetes mellitus inadequately controlled with metformin, sulfonylurea, and/or insulin, who have failed or a | Recommended · restricted | Mar 2026 |
| Tofersen | Neurology | Treatment of amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. | Recommended · restricted | Mar 2026 |
| Trastuzumab Deruxtecan | Oncology | Treatment of adult patients with hormone receptor positive (HR-positive) human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralo | Not recommended | Mar 2026 |
| Upadacitinib | Gastroenterology | Complex refractory fistulising Crohn's disease with externally draining enterocutaneous or rectovaginal fistula. | Recommended · restricted | Mar 2026 |
| Ustekinumab | Dermatology | Treatment of adult patients with severe chronic plaque psoriasis and severe psoriatic arthritis. | Recommended | Mar 2026 |
| Vorasidenib | Oncology | Treatment of patients with WHO Grade 2 IDH-mutant astrocytoma or oligodendroglioma with residual or recurrent disease after at least one pri | Recommended · restricted | Mar 2026 |
| Elranatamab | Haematology | Treatment of patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteaso | — | Dec 2025 |
| Eplerenone | Cardiovascular | Chronic heart failure with left ventricular ejection fraction ≤40%, either within 3-14 days following acute myocardial infarction or in symp | Recommended | Dec 2025 |
| Pembrolizumab | Oncology | Treatment of unresectable advanced and metastatic cancers, excluding adjuvant, neoadjuvant, or perioperative settings, and excluding tumours | Recommended | Dec 2025 |